Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics of Energy -- Ignore unavailable to you. Want to Upgrade?

To: Sdgla who wrote (59895)

10/29/2014 3:40:26 PM

From: Wharf Rat

Read Replies (1) | Respond to of 86356

And yet, all those people were cured without it.
Maybe they were smoking weed.

Bayer urges NHS CCGs to consider Sativex treatment for MS10 October 2014 13:24 in Pharmaceutical Company Product News

Bayer has urged NHS clinical commissioning groups (CCGs) to continue to consider Sativex as a potential treatment pathway for patients with multiple sclerosis (MS), despite clinical guidance to the contrary.

According to the National Institute for Health and Care Excellence's (Nice's) recommendations for the management of MS in primary and secondary care, Sativex - a cannabis-derived oromucosal spray - is not sufficiently cost-effective for NHS treatment.

However, Bayer hopes CCGs will consider funding the drug outside of national guidelines, based on its proven benefits and a favourable pricing framework.

zenopa.com